NCT04964024 is a clinical trial of SARS-CoV-2 antibodies in COVID-19 Infection, sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT04964024?

NCT04964024 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT04964024?

Interventions in NCT04964024: SARS-CoV-2 antibodies.

What condition does NCT04964024 study?

NCT04964024 studies COVID-19 Infection.

Is NCT04964024 still recruiting?

NCT04964024 is currently completed. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT04964024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes

Completed Last updated 19 July 2022

What this trial tests

trial testing SARS-CoV-2 antibodies in COVID-19 Infection in 1,293 participants. Completed in 15 May 2022.

Timeline

15 July 2021

Primary endpoint
15 May 2022

15 May 2022

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,293
Start date	15 July 2021
Primary completion	15 May 2022
Estimated completion	15 May 2022
Sites	1 location across France

Drugs / interventions tested

SARS-CoV-2 antibodies

Conditions studied

COVID-19 Infection — all drugs for COVID-19 Infection →

Sponsor

Central Hospital, Nancy, France

Who can join

Adults 20 to 110, any sex, with COVID-19 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease. Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Anti-spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents.
Jeulin H, Labat C, Duarte K, Toupance S, et al · · 2022 · cited 19× · PMID 35484977 · DOI 10.1111/jgs.17837
Risk of SARS-CoV-2 Infection in Nursing Home Residents According to COVID History and IgG Anti-Spike Antibody Levels.
Jeulin H, Labat C, Benetos A. · · 2023 · PMID 36463969 · DOI 10.1016/j.jamda.2022.11.004
History of SARS-CoV-2 infection, anti-spike IgG antibody kinetics and neutralization capacities following the second and third dose of BNT162b2 vaccine in nursing home residents
Jeulin H, Labat C, Duarte K, Toupance S, et al · · 2022 · DOI 10.1101/2022.02.07.22270557
Comparative analysis of post-vaccination anti-spike IgG antibodies in old Nursing Home Residents and in middle-aged Healthcare workers
Jeulin H, Craus D, Labat C, Benetos A. · · 2021 · DOI 10.1101/2021.08.03.21261014

Verify or expand the search:

Other recruiting trials for COVID-19 Infection

Currently open trials in the same condition.

NCT07013474 — A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · recruiting
NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05672355 — A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia · Phase 2 · recruiting
NCT05774093 — Evaluation of COVID-19 Immune Barrier and Reinfection Risk · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04964024 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04964024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing